Markets
JNJ

J&J Ordered To Pay $8 Bln In Case Over Male Breast Growth On Anti-psychotic Drug

(RTTNews) - A Philadelphia jury ordered that Johnson & Johnson (JNJ) must pay $8 billion in punitive damages to a man who claimed the company failed to warn that boys using its Risperdal anti-psychotic drug could grow breasts.

The Philadelphia Common Pleas Court jury agreed that Janssen Pharmaceuticals, a Johnson & Johnson subsidiary, engaged in a "pervasive nationwide effort to illegally market Risperdal and downplay its very serious risks on a systemic level."

The case was brought by a Maryland resident, Nicholas Murray who "developed female breast tissue" after taking Risperdal, the Court record showed. In 2015, Murray had won $680,000 in compensatory damages over his claims.

Johnson & Johnson called the $8 billion award a "clear violation of due process" and said it would immediately appeal the verdict.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

JNJ

Latest Markets Videos

    RTTNews

    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More